ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRQR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $146.98M
- EPS (TTM)
- -$0.43
- Dividend yield
- None
- 52-week range
- 1.00 – 2.49
- Day range
- 1.00 – 1.07
- Volume / Avg
- 920.56K / 793.64K
- Beta
- —
- Shares outstanding
- 141.33M
52-week range
PRQR stock today
ProQR Therapeutics N.V. (PRQR) closed at $1.04 on Nov 20, down 0.95% (-$0.01), versus the S&P 500's 3.70% decline. Shares are 58.1% below their 52-week high of $2.49, set on Dec 16, 2025 and 4.0% above the 52-week low of $1.00, near the bottom of the past year's range. PRQR is down 48.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.5%.
ProQR Therapeutics N.V. has posted a net loss over the last twelve months (EPS of -$0.43), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ProQR Therapeutics N.V.
Company profileProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel Anton de Boer
- Headquarters
- Leiden
- Employees
- 186
- IPO year
- 2014
- Website
- proqr.com
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$7.56+626.92%
- Strong buy 1
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.12 vs $-0.11
- Surprise
- -9.09%
PRQR news
All PRQR news- ProQR Therapeutics N.V. Reports Third Quarter 2026 Operating and Financial ResultsNasdaq
- ProQR Therapeutics N.V. Announces Third Quarter 2026 Operating and Financial ResultsNasdaq
- ProQR Therapeutics Q3 Sales IncreaseNasdaq
- ProQR Therapeutics N.V. to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesNasdaq
- ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesGlobeNewswire
ProQR Therapeutics N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs PRQR |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs PRQR |
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs PRQR |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs PRQR |
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs PRQR |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs PRQR |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs PRQR |
| ZNTLZentalis Pharmaceuticals Inc. | 1.36 | 0.00% | $133.64M | vs PRQR |
Indexes, lists and sector
ProQR Therapeutics N.V. stock FAQ
What is ProQR Therapeutics N.V.'s stock price today?
PRQR last traded at $1.04 as of Nov 20, 4:00 PM EST, down 0.95% on the day. Prices are delayed at least 15 minutes.
Who is ProQR Therapeutics N.V.'s CEO?
Mr. Daniel Anton de Boer is the chief executive officer of ProQR Therapeutics N.V., which has about 186 employees.
What is the PRQR 52-week high?
The 52-week high for PRQR is $2.49 and the 52-week low is $1.00. The stock is currently 58.1% below its high.